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A B S T R A C T
This review summarises genetic studies in which calcium channel genes have been connected to the
spectrum of neuropsychiatric syndromes, from bipolar disorder and schizophrenia to autism spectrum
disorders and intellectual impairment. Among many other genes, striking numbers of the calcium
channel gene superfamily have been implicated in the aetiology of these diseases by various DNA
analysis techniques. We will discuss how these relate to the known monogenic disorders associated with
point mutations in calcium channels. We will then examine the functional evidence for a causative link
between these mutations or single nucleotide polymorphisms and the disease processes. A major
challenge for the future will be to translate the expanding psychiatric genetic ﬁndings into altered
physiological function, involvement in the wider pathology of the diseases, and what potential that
provides for personalised and stratiﬁed treatment options for patients.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Abbreviations: DISC1, Disrupted in Schizophrenia 1; fMRI, functional magnetic resonance imaging; FMRP, Fragile X mental retardation protein; GWAS, genome wide
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Excitable cells can be deﬁned as those that are able to ﬁre an
action potential in response to depolarization, or more loosely,
they contain functional voltage-gated ion channels. Neurons and
muscle cells are conventionally excitable, but many other cell
types show oscillatory changes in voltage, dependent on calcium
entry (Hu et al., 2012). Free intracellular Ca2+ is normally controlled
at a low level in the cytoplasm (10–100 nM), by plasma membrane
and endoplasmic/sarcoplasmic reticulum pumps and exchangers,
as well as by mitochondrial sequestering. Voltage-gated calcium
channels react to membrane potential depolarization by opening
to allow calcium ions to ﬂow down their electrochemical gradient.
Ca2+ entry, particularly but not exclusively through voltage-gated
calcium channels, provides an elevation of calcium ions to drive
many processes. These include hormone secretion, neurotrans-
mitter release, calcium-dependent gene transcription, and also
spontaneous pacemaker activity in some neurons, muscles, and
secretory cells (Mangoni et al., 2003; Putzier et al., 2009; Guzman
et al., 2009; Hu et al., 2012; Striessnig et al., 2015). Ca2+ activates
numerous calcium-dependent enzymes, including kinases, phos-
phatases, and proteases, and also activates ion channels, including
Ca2+-activated K+ channels. It therefore has multiple effects on cell
function depending crucially on where Ca2+ entry occurs (Catterall
et al., 2013; Cohen et al., 2015). In skeletal muscle, the voltage-
gated calcium channels link depolarization to release of internal
Ca2+ from sarcoplasmic reticulum in the process of excitation-
contraction coupling (Bannister and Beam, 2013), and in cardiac
and smooth muscle, the Ca2+ entry through voltage-gated calcium
channels mediates Ca2+-induced Ca2+ release (Fabiato, 1985;
Valdeolmillos et al., 1989).
Because of the key roles of voltage-gated calcium channels in
processes that are so critical for cellular function, it is essential that
they are inserted into the plasma membrane in a regulated
manner. Muscles, secretory cells, and neurons all have specialized
regions of their plasma membrane where voltage-gated calcium
channels are found to be clustered in an ordered manner. The
distinctive biophysical properties that are intrinsic to the different
subtypes of pore-forming calcium channel subunits, as well as
their regulation by auxiliary subunits and other binding proteins,
ensure that the functions of voltage-gated calcium channels are
customized for the different roles that they fulﬁl in particular
subcellular locations and cells in which they occur. It also goes
some way to explaining why there are so many different diseases
associated, either directly or indirectly, with voltage-gated calcium
channel dysfunction.
There is currently a great deal of interest in voltage-gated
calcium channels, with regard to their involvement in the genesis
of a spectrum of psychiatric disorders; particularly autism
spectrum disorder, schizophrenia, and bipolar disorder, and thisreview aims to bring together both the genetic and the available
functional information.
2. Voltage-gated Calcium Channel Classiﬁcation—Genes and
Proteins
2.1. Calcium Channel Subtypes
In order to understand how voltage-gated calcium channels
may relate to neuropsychiatric diseases, it is important to be aware
of the classiﬁcation of these channels, their different properties
and functions, as well as their distribution and interaction with
other proteins, which are summarized in this section.
The ﬁrst clear evidence for more than one category of voltage-
gated calcium channel was that currents underlying the calcium
conductances in several cell types had distinct high- and low-
voltage-activated components, which also had distinctive kinetic
properties (Carbone and Lux, 1984; Nilius et al., 1985). Pharmaco-
logical tools were essential to further deﬁne these components of the
calcium currents found in different neurons and muscle cells. The
development of calcium channel blockers then allowed particular
subtypes of voltage-gated calcium channel to be more clearly
deﬁned. The ﬁrst organic blockers to be characterised were those
that selectively targeted a subclass of high-voltage activated
channels, prevalent in cardiac and smooth muscle. These drugs
included verapamil, diltiazem, and 1,4-dihydropyridines (Flecken-
stein, 1983; Triggle, 1987). The channels that were sensitive to these
drugs were termed L-type, particularly because the single-channel
openings were of large conductance (Nowycky et al., 1985a).
Following the discovery of a number of cone shell and spider
peptide toxins that selectively blocked different voltage-gated
calcium channel components, further subtypes of voltage-gated
calcium channel could be delineated on both physiological and
pharmacological bases. In addition to the L-type channels, these were
namedtheN-type,P/Q-type,andR-typeforthehigh-voltageactivated
calcium channels, whereas the low-voltage activated channels were
termed T-type (Nowycky et al., 1985b; Fox et al., 1987a, 1987b; Mintz
et al., 1992b; Zhang et al., 1993; for review, see Dolphin, 2006).
2.2. Calcium Channel Subunit Structure
Voltage-gated calcium channels can consist of maximally four
different subunits, the pore-forming a1 subunit, as well as the
auxiliary a2d and b (and in some cases g) subunits. The a1
subunits principally determine the kinetics, voltage dependence,
single-channel conductance, and pharmacology of the voltage-
gated calcium channels, although many of these properties can be
modulated by the b and a2d auxiliary subunits, which also have
signiﬁcant roles in voltage-gated calcium channel trafﬁcking.
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of 10 different mammalian calcium channel a1 subunit gene
products, encoded by the CACNA1 genes. The nomenclature used
for the channel and gene names is described here (Catterall et al.,
2003) and is summarized in Fig. 1A. In the case of the CaV1.1–
CaV1.4 channels (known as L-type channels), these are encoded by
CACNA1S, C, D, and F, respectively. The CaV2.1–CaV2.3 channels
(termed P/Q-, N-, and R-type channels) are encoded by CACNA1A, B,
and E, respectively. Both the CaV1 and CaV2 channels form an a1/b/
a2d complex, co-assembling with one of four a2d subunits
(encoded by CACNA2D1–4) and one of four b subunits (encoded
by CACNB1–4) (Fig. 1B). For the CaV3 channels (encoded by
CACNA1G, H, and I), the a1 subunits can form functional channels
alone, but may also associate with other proteins.
All of the subunit transcripts may exhibit a number of variants,
as a result of alternative splicing events. The different channel
isoforms and possible combinations make for an enormous
potential diversity in the properties and function of the calcium
channel complexes.
The auxiliary a2d and b subunits also have major roles in
trafﬁcking the CaV1 and CaV2 channels to the plasma membrane
and to speciﬁc domains of polarized cells, including neurons
(Dolphin, 2012; D’Arco et al., 2015). From puriﬁcation studies, the
L-, P/Q-, and N-type calcium channels were all found to be
associated with auxiliary b and a2d subunits (Tanabe et al., 1987;
Witcher et al., 1993; Liu et al., 1996). However, the association ofFig. 1. Calcium channel a1, b, and a2d subunits, and their topology. (A) Nomenclature of 
rationalised protein names (CaV nomenclature), and names used in physiological disco
voltage-activated. (B) Calcium channel a1, b, and a2d subunit topology. The a1 subunit ha
Each domain has six transmembrane segments (S1–S6), including the S4 voltage sensoa2d subunits with the calcium channel complexes was found to be
relatively weak and easily disrupted (Takahashi et al., 1987;
Mu¨ller et al., 2010), compared to the more robust interaction of
the b subunits, which show a low nM afﬁnity for interaction with
the I–II linker of CaV1 and CaV2 channels (Pragnell et al., 1994;
Canti et al., 2001). Despite this difference, both the b and a2d
subunits markedly enhance the expression and function of these
channels.
Skeletal muscle calcium channels are also found to be
associated with a g subunit (termed g1, encoded by CACNG1)
(Jay et al., 1990), but other so-called g subunits (encoded by
CACNG2–8), do not appear to form part of cardiac (Walsh et al.,
2009) or neuronal (Moss et al., 2002; Mu¨ller et al., 2010) calcium
channel complexes, and are better considered as transmembrane
AMPA-glutamate receptor modifying proteins.
2.3. Voltage-gated Calcium Channel Distribution
CaV1.1 is the skeletal muscle isoform of this family and shows
very low expression in brain. In contrast, CaV1.2 (a1C) encoded
by CACNA1C is the predominant calcium channel in ventricular
cardiac muscle and is also present in smooth muscle, many
secretory cells, and throughout the brain (Striessnig et al., 2014).
CaV1.3 (a1D) encoded by CACNA1D has a more restricted
distribution than CaV1.2, being particularly important in
sinoatrial node in the heart and in inner hair cells of the earcalcium channel subunits, including gene name, initial names of cloned a1 subunits,
very of the channels. HVA, LVA = classical deﬁnition of channels as high- or low-
s 24 transmembrane segments, comprising four homologous domains, labelled I–IV.
r (yellow), and the S5–S6 pore-forming segments (blue).
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although it is also present in the brain. The differential
distribution and function(s) of CaV1.2 and CaV1.3 in various
brain regions is discussed in detail in a recent review (Zamponi
et al., 2015). CaV1.3 is activated at lower voltage thresholds than
CaV1.2 (Koschak et al., 2001; Helton et al., 2005). CaV1.4 (a1F),
encoded by CACNA1F, shows very restricted expression, mainly
in the retina (Mansergh et al., 2005). The L-type channels,
CaV1.2 and CaV1.3, both have a postsynaptic role to play in
dendritic signalling, and in signalling to the nucleus in a process
termed excitation–transcription coupling (Wheeler et al., 2012;
Striessnig et al., 2014).
Members of the CaV2 class of channels have a predominantly
neuronal distribution. CaV2.1 (a1A) is the molecular equivalent of
P/Q-type calcium channels and is encoded by CACNA1A (Stea et al.,
1994). CaV2.1 channels are present throughout the brain and
particularly prevalent in cerebellum (Ophoff et al., 1996). They are
the predominant calcium channels involved in neurotransmission
in most mature central presynaptic terminals investigated
(Westenbroek et al., 1995; Iwasaki et al., 2000; Ishikawa et al.,
2005; Nakamura et al., 2015) and also make up a substantial
proportion of the calcium current recorded in many neuronal cell
bodies, particularly Purkinje neurons (Mintz et al., 1992a;
Westenbroek et al., 1995). CaV2.2, or a1B, is the molecular
counterpart of the N-type calcium channels and is encoded by
CACNA1B (Williams et al., 1992). It is widely distributed throughout
the central (Westenbroek et al., 1992) and peripheral nervous
systems (Lipscombe et al., 1988; Boland et al., 1994; Wheeler et al.,
1994) and is particularly important for neurotransmission early in
development and also in the mature peripheral nervous system,
including nociceptive pathways (Chaplan et al., 1994; Bowersox
et al., 1996; Iwasaki et al., 2000). CaV2.3 (a1E) is encoded by
CACNA1E (Soong et al., 1993). It was originally described as a low-
voltage activated channel, but is now understood to correspond, at
least in part, to the residual R-type calcium current, present after
pharmacological block of N-type, P/Q-type, and L-type channels
(Zhang et al., 1993; Tottene et al., 2000; Wilson et al., 2000).
CaV2.3 is widely distributed in many brain regions including the
hippocampus and is present both pre- and post-synaptically
(Parajuli et al., 2012).
In neurons, the CaV2 channels, particularly CaV2.1 and CaV2.2
(P/Q- and N-type calcium channels), are essential in most synapses
for supplying the Ca2+ that mediates presynaptic transmitter
release (Takahashi and Momiyama, 1993; Wu et al., 1999; Cao and
Tsien, 2010) and there is a developmental switch towards greater
reliance on CaV2.1 channels at many synapses in mature animals
(Iwasaki et al., 2000). CaV2.3 has been found to be differentially
important for triggering spontaneous release of glutamate
(Ermolyuk et al., 2013), although there are caveats to the use of
the blocker SNX-482 to delineate the physiological roles of CaV2.3
(Kimm and Bean, 2014).
The CaV3 group of channels (a1G, a1H, and a1I), encoded by
CACNA1G, H, and I (Cribbs et al., 1998; Perez-Reyes, 1998) are the
molecular counterparts of the T-type calcium channels and are
more divergent with respect to their sequence from the high-
voltage activated channels (Perez-Reyes et al., 2009).
CaV3 channels are widely distributed in excitable cells. In the
brain, they are present in most neurons and are particularly
prevalent in the thalamus (Perez-Reyes, 2003). CaV3 channels (and
also CaV1.3 which is relatively low-voltage activated) have
important roles in neuronal excitability and pacemaker activity
(Perez-Reyes, 2003; Guzman et al., 2009; Putzier et al., 2009). As
well as having a postsynaptic distribution and function, at some
synapses they also have a presynaptic function to modulate, and in
some cases directly mediate, transmitter release (Huang et al.,
2011; Carbone et al., 2014).2.4. Voltage-gated Calcium Channel Pharmacology
CaV1 channels are inhibited by a number of L-type calcium
channel blockers, many of which are in clinical use, particularly for
hypertension. The most widely used are dihydropyridines, such as
nifedipine. Other drugs that block L-type calcium channels,
including verapamil and diltiazem, interact with overlapping
high-afﬁnity drug-binding sites on these channels (Striessnig et al.,
1990, 1991). These drugs inhibit CaV1.2 more effectively than
CaV1.3 or CaV1.4, partly because the drugs have a much higher
afﬁnity for the inactivated state of the channels, and CaV1.2 shows
more inactivation than CaV1.3 or CaV1.4 (for review, see Zamponi
et al., 2015). Furthermore, because vascular smooth muscle
generally sits at a more depolarized membrane potential than
most neurons or cardiac ventricular muscle, CaV1.2 in these cells is
preferentially targeted by the voltage-dependent dihydropyridine
antagonists (Bean et al., 1986). An additional nuance is that
although these drugs can bind to the skeletal muscle calcium
channel CaV1.1, the primary essential voltage-sensor function of
this channel is not signiﬁcantly inhibited by these calcium channel
blockers.
Members of the CaV2 class of channels are not blocked by low
concentrations of dihydropyridine antagonists. CaV2.1 can be
blocked by certain peptide toxins such as v-agatoxin IVA (Mintz
et al., 1992b). CaV2.2 is irreversibly inhibited by the peptide toxin,
v-conotoxin GVIA (Reynolds et al., 1986), and reversibly blocked
by other related v-conotoxins (McDonough et al., 1996), one of
which (v-conotoxin MVIIC) is licensed for use in certain chronic
pain conditions (Staats et al., 2004). R-type calcium current is
deﬁned as that which is present after pharmacological block of N-
type channels with v-conotoxin GVIA, block of P/Q-type channels
with v-agatoxin IVA, and block of L-type channels with a selective
dihydropyridine antagonist (Zhang et al., 1993). By this process of
elimination, it is thought to be the molecular counterpart of
CaV2.3 channels. R-type current can be blocked by a peptide toxin
SNX 482 (Newcomb et al., 1998; Bourinet et al., 2001); however
this toxin also inhibits L-type channels (Bourinet et al., 2001) and
some K+ currents (Kimm and Bean, 2014), and thus cannot readily
be used to deﬁne the role of CaV2.3 channels physiologically.
There are a number of pharmacological agents that target
CaV3 channels, including mibefradil (Mishra and Hermsmeyer,
1994; Ertel and Clozel, 1997), although this compound is poorly
selective and also targets other calcium channels (Bezprozvanny
and Tsien, 1995). In contrast, TTA-A2 and TTA-P2 are selective
CaV3 blockers (Choe et al., 2011; Francois et al., 2013), which are of
use in deﬁning the physiological roles of T-type channels. Z944 is
also a selective T-type channel blocker (Tringham et al., 2012), with
therapeutic potential (Lee, 2014).
3. Genetic Analysis of Neuropsychiatric Syndromes
Genetic analysis of disorders that do not show clear Mendelian
inheritance can involve a number of different strategies. Histori-
cally, the candidate gene strategy for schizophrenia was often
centred on the hypothesis that monoaminergic systems were
disrupted, based on the ability of drugs (for example, chronic
amphetamine), to mimic some of the symptoms of schizophrenia,
and the fact that the mainstay of drug treatment of schizophrenia
remains the dopamine D2 receptor antagonists. However, these
approaches did not lead to useful identiﬁcation of genes disrupted
in these pathways, in part because, by current standards, the early
candidate gene studies used very small samples, therefore they did
not have adequate statistical power to detect true risk alleles even
if they existed in the candidate genes tested (Mitchell, 2011).
Nevertheless, for a few of these candidate genes (notably the gene
encoding the D2 dopamine receptor, DRD2), an association has
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studies (GWAS) (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014).
A second linkage analysis approach is aimed at identiﬁcation of
the genes mutated in rare families in which the disorder appears to
be inherited. For example, the gene Disrupted in Schizophrenia 1
(DISC1) was identiﬁed in this way, by virtue of its association with a
chromosomal translocation breakpoint (Millar et al., 2000).
However, this type of study has had limited success with respect
to understanding the aetiology of common psychiatric disorders,
because of their inherently complex polygenic nature. In large
resequencing studies, the hypothesis that genes, such as DISC1,
contain uncommon allelic variants that are of relevance to
schizophrenia has not been borne out (Crowley et al., 2013).
Nevertheless, meta-analyses have shown some consistency across
linkage studies (Lewis et al., 2003).
Thus, aided by the rapid advances in high-throughput
genotyping and sequencing technologies, other unbiased techni-
ques are now widely employed. These include GWAS, which
examine the frequencies of common genetic variants represented
by single nucleotide polymorphisms (SNPs), across a large number
of subjects with the disorder in question, compared to a set of
matched controls. SNPs are deﬁned as point mutations occurring
with a frequency of greater than 1 in 100, and subjects can
therefore be either heterozygous or homozygous for these alleles.
The deﬁnition of an allele is a particular sequence at any given
locus in the genome where more than one sequence is present in
the population. SNPs are found throughout the genome and most
are inevitably in non-coding regions. Furthermore, it is not usually
known whether the implicated SNP actually represents the
disease-associated alteration, or whether it is in linkage disequi-
librium with the variant causing the functional effect. The effect
size of individual SNPs associated with common psychiatric
disorders is generally small (odds ratio <1.2). However, studies
have now shown that collectively, common alleles can account for
a large fraction of the genetic liability to develop psychiatric
disorders (Purcell et al., 2009). For example, one comprehensive
GWAS calculated that common SNPs can collectively account for at
least 32% of the variance in liability to develop schizophrenia in the
population studied (Ripke et al., 2013). GWAS have identiﬁed a
number of associations, surpassing genome-wide levels of
signiﬁcance, in calcium channel genes for these diseases, as
described below.
Evidence that rare mutations in calcium channel genes also
have an important role in the development of neuropsychiatric
disorders has primarily come from whole exome sequencing
studies. Whole exome sequencing is best suited for discovering
rare coding mutations, such as single nucleotide variants, which
can either be synonymous (not change the amino acid sequence)
or non-synonymous, and either change amino acid residues
(missense) or produce premature truncations by mutation to a
stop codon. They may also identify deletion or insertion of one or
more base pairs (indels), which cause truncation by changing the
coding frame, usually resulting in introduction of a premature
stop codon preceded by one or more aberrant residues. These
studies can be performed in a number of different ways, either de
novo mutations are identiﬁed in cases with the disorder and
compared with those found in matched controls; or rare/de novo
mutations in affected subjects are compared to their own
unaffected parents and sibling(s) (trio/quartet studies) to identify
variants associated with the condition. Since it has become clear
that all humans carry a large number of rare, potentially
deleterious mutations (Keinan and Clark, 2012; Gao et al.,
2015; Sulem et al., 2015), these types of systematic controls
are important, if one is to infer a causative role for such mutations
in the disorder under examination. It should also be noted thatgain-of-function mutations are harder to predict than loss of
function mutations and therefore could be missed by any study
(Flanagan et al., 2010).
Studies investigating rare copy number variations (these are
>1 kb in size and consist of large deletions, duplications, or other
more complex rearrangements) have also identiﬁed calcium
channel genes to be associated with some of these disorders
(see below). It is likely that the functional consequence of whole
gene deletion or duplication is altered gene dosage (Lee and
Scherer, 2010). The functional consequences of copy number
variations that partially intersect a gene are more difﬁcult to
interpret, but they could have similar effects to loss of function
single nucleotide variants/indels.
Given the evidence that the spectrum of psychiatric disorders
under discussion in this review all involve synaptic dysfunction
(Fatemi and Folsom, 2009), and a large number of synaptic proteins
harbour disease-associated SNPs, deleterious mutations, and copy
number variations (Ting et al., 2012; Malhotra and Sebat, 2012), it
is perhaps not surprising that voltage-gated calcium channels are
one of the groups of synapse-associated proteins observed to be
involved in these disorders, from many studies. This will be
explored in Sections 4 and 5.
4. Calcium Channel Genes Identiﬁed from GWA Studies of
Psychiatric Disorders
SNPs in calcium channel genes have been identiﬁed as risk
alleles in a spectrum of psychiatric disorders (Cross-disorder group
of Psychiatric Genomics Consortium, 2013; Schizophrenia Work-
ing Group of the Psychiatric Genomics Consortium, 2014). As
described above, SNPs are point mutations occurring with a
frequency >0.01. Although the identiﬁed SNP does not necessarily
directly cause the biological effect, it must be in linkage
disequilibrium with the causative mutation; thus the position of
the associated SNP is of functional importance. Most of the
associated SNPs are in introns or intergenic regions, where they
may be involved in cis-regulatory elements including promoter
and enhancer regions or regulation of alternative splice variant
expression. cis-elements are situated within or near to the
regulated gene and contain binding sites for regulatory factors
required for tissue-speciﬁc and temporal expression of genes.
The common allele associations identiﬁed in calcium channel
genes, particularly those found in CACNA1C (SNP rs1006737 and
other SNPs in linkage disequilibrium with this SNP), have been
reproduced in multiple studies to be associated with psychiatric
disorders, including schizophrenia (http://bdgene.psych.ac.cn/
geneDetail.do?name=CACNA1C). For example, in a recent study,
SNP rs4765905 in CACNA1C showed an association with schizo-
phrenia with an odds ratio of 1.0944 and P = 1.2e-8 (Hamshere
et al., 2013). Many of these SNPs are quite common in the
population, for example, at rs1006737 the SNP can be either G or A,
with A being the risk variant and occurring in the general
population with a frequency of about 0.33. In the most recent
study, in which 108 SNPs were identiﬁed as risk factors in
schizophrenia (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014), three calcium channel gene SNPs
were identiﬁed as risk factors with genome-wide levels of
signiﬁcance. For CACNA1C (SNP rs2007044), the odds ratio for
schizophrenia was 0.912 for the common allele (P = 3.22e-18). For
CACNB2 (SNP rs7893279), the odds ratio was 1.125 (P = 1.97e-12),
and for CACNA1I (Chr22_39987017_D) the odds ratio was 0.930
(P = 4.725e-11). SNPs in several of these genes, particularly
CACNA1C, had also been identiﬁed previously, and subsequently
conﬁrmed with greater power, in studies of people with bipolar
disorder (Ferreira et al., 2008; Schizophrenia Psychiatric Genome-
Wide Association Study (GWAS) Consortium., 2011; Lee et al.,
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Genomics Consortium, 2013; Green et al., 2013; Schizophrenia
Working Group of the Psychiatric Genomics Consortium, 2014;
Nurnberger et al., 2014). It is important to note that some identiﬁed
SNPs are associated with a speciﬁc susceptibility to either bipolar
disorder or schizophrenia, whereas for two of the genes, CACNA1C
and CACNB2, the SNPs were found to confer susceptibility to
schizophrenia, bipolar disorder, and also to major depressive
disorder (Green et al., 2010; Cross-disorder group of Psychiatric
Genomics Consortium, 2013). Indeed SNPs in multiple voltage-
gated calcium channel subunit genes were associated with disease
in this ﬁve disorder meta-analysis, including the a1 subunit genes
CACNA1C, CACNA1D, CACNA1E, CACNA1S, the a2d subunit genes
CACNA2D2 and CACNA2D4, and the b subunit gene CACNB2 (Cross-
disorder group of Psychiatric Genomics Consortium, 2013).
SNPs in other calcium channel genes have been found to be
associated with autism spectrum disorder, in particular, the T-type
calcium channel genes CACNA1G (Strom et al., 2010; Lu et al., 2012),
and CACNA1I (Lu et al., 2012). In the latter study, 2781 parent/
affected child trios were examined, and associations were
considered signiﬁcant if they survived correction for the 10 genes
examined (Lu et al., 2012). Furthermore, although it is not a
psychiatric disorder, variations in central pain perception and
processing have been associated with an SNP in CACNA2D3 (Neely
et al., 2010).
5. Rare Mutations in Calcium Channel Genes in Psychiatric
Disorders
It has recently been demonstrated that healthy individuals
exhibit multiple rare de novo or inherited neutral and disruptive
mutations in coding sequences (Keinan and Clark, 2012;
MacArthur et al., 2012). This was well illustrated by an ion
channel exome sequencing study of subjects with epilepsy,
compared to controls which did not ﬁnd an excess of rare
potentially causative mutations in the affected individuals
(Klassen et al., 2011).
In the largest whole exome sequencing study of schizophrenia
to date, rare (less than 1 in 10,000), disruptive alleles were
signiﬁcantly enriched in cases, among 2500 genes previously
implicated in schizophrenia. At the level of gene sets, disruptive
alleles were enriched in voltage-gated calcium channels, with the
strongest signal found for ultra-rare alleles observed only once in
the sample (12 in cases, one in controls; P = 2  103, odds
ratio = 8.4). Strikingly, in this study, the voltage-gated calcium
channel gene subset was highly represented by CACNA1B,
CACNA1C, CACNA1H, CACNA1S, CACNB4, and also CACNA2D1,
CACNA2D2, and CACNA2D4 (Purcell et al., 2014). Two mutations
in CACNA1C were identiﬁed; this was one of the calcium channel
genes previously implicated in several studies by GWAS of both
bipolar disorder and schizophrenia (see section above). Both these
mutations are truncating and predicted to cause loss of function.
We show, in Fig. 2, the positions of a number of the mutations in
calcium channel genes, in CACNA1B, CACNA1C, CACNA1H, CACNA1S;
CACNA2D1, CACNA2D2, CACNA2D4, and CACNB4, described in
Purcell et al. (2014). All these mutations involve either frameshift,
mutation to a stop codon, or splice site mutations, and from their
position all are likely to cause partial or complete loss of function
(Fig. 2). Given their rarity, individuals with these mutations are
likely to be heterozygous and therefore carry one non-mutated
allele.
A recent study has highlighted the importance of accurate
prediction of whether transcripts containing a premature stop
codon will trigger nonsense-mediated mRNA decay (Rivas et al.,
2015). In the case of the truncated a1 subunits, if the mRNA was
not completely degraded by nonsense-mediated decay, and if apartial protein were translated, it could potentially behave in a
dominant-negative manner, as has been shown for truncated
CaV2.1, CaV2.2, and CaV3 channels (Raghib et al., 2001; Page et al.,
2004, 2010; Mezghrani et al., 2008), and this may potentially occur
for CaV2.1 in the monogenic disorder episodic ataxia 2 (Jouvenceau
et al., 2001; Page et al., 2004; Mezghrani et al., 2008). It should also
be noted that CACNA2D4, encoding a2d-4, implicated in Purcell
et al. (2014) (Fig. 2) is primarily expressed in the retina (Lee et al.,
2015).
Although not directly related to calcium channels, it is of
interest that in another whole exome sequencing study in
schizophrenia (Fromer et al., 2014), disruptive mutations were
identiﬁed in members of the postsynaptic density gene set,
including the gene for a calcium activated protease (CAPN5). This
gene encodes calpain, which can be activated in dendrites by
voltage-gated calcium channels (Kanamori et al., 2013).
Exome sequencing in individuals with autism spectrum
disorder also identiﬁed an excess of de novo deleterious mutations
(nonsense, splice site, and frame shifts) in cases, compared to
unaffected siblings (Iossifov et al., 2012). In a recent analysis of de
novo, inherited and case–control mutations identiﬁed from exome
sequence of 3871 autism cases and 9937 ancestry-matched or
parental controls, CACNA2D3 was implicated as a risk gene
following the identiﬁcation of two de novo loss of function
mutations in cases and none in controls (false discovery rate
<0.05)(De Rubeis et al., 2014). Interestingly, in a previous study of
343 families, each with a single child on the autism spectrum, and
at least one unaffected sibling, a single de novo splice site mutation
was found in CACNA2D3, one of many gene-disrupting mutations
identiﬁed (Iossifov et al., 2012). A copy number variation study in
autism also revealed a deletion in CACNA2D3 (Girirajan et al.,
2013). CACNA2D3 encodes a2d-3, which is widely expressed in the
brain and involved in neurotransmitter release (Hoppa et al., 2012)
and synaptic function (Pirone et al., 2014).
In the same large exome sequencing study described above that
identiﬁed CACNA2D3, ﬁve mutations were also identiﬁed in
CACNA1D (De Rubeis et al., 2014); these included G407R (in exon
8a) and A749G, both of which were described previously (Iossifov
et al., 2012; O’Roak et al., 2012) and subsequently shown to cause a
gain of function (Pinggera et al., 2015). Other mutations identiﬁed
were A59V, which maps to an N-terminal sequence involved in
Ca2+-dependent inactivation (Dick et al., 2008), and two C-terminal
mutations (S1977L and R2021H), which are in a C-terminal
proline-rich domain, involved in interaction with SHANK3 (Zhang
et al., 2005).
Furthermore, in a whole genome sequencing study of autism
spectrum disorder, a rare missense mutation in CACNA1C (R1522Q)
in the proximal C-terminus was identiﬁed in a proband with
autism but it was also found in an unaffected sibling, and also their
father (who had the cardiac disorder, Wolff Parkinson White
syndrome) (Jiang et al., 2013). In this family, it was therefore
unclear whether the mutation in CACNA1C was causative of autism.
In another study, three rare missense variants in the coding region
of CACNB2 (G167S, S197F, and F240L) were identiﬁed in autism
spectrum disorder probands, and absent from controls, following
exome sequencing of this gene for 259 controls and 155 probands
(Breitenkamp et al., 2014). However, the variants showed
incomplete segregation with the disorder in the families affected.
Nevertheless, all three variants showed altered time-dependent
inactivation of Ca2+ currents, although two mutations were
associated with signiﬁcantly slower inactivation, whereas the
third mutation (F240L) showed increased inactivation (Breiten-
kamp et al., 2014). More recently, in an exome sequencing study of
autism risk genes, investigating families where two siblings were
autistic, a mutation in CACNB2 (V2D) was identiﬁed as one of
relatively few genes that showed mutations in both affected
Fig. 2. Mutations identiﬁed in exome sequencing. Analysis of mutations that are highly likely to be disruptive, identiﬁed in a whole exome sequencing of schizophrenia
(Purcell et al., 2014). The line in each case represents the appropriate full-length gene. The chromosome number is indicated next to the gene name. The beginning and end
nucleotide position of each gene on the chromosome is shown (using GRCh 37). Nucleotide mutations are indicated with an arrow below the line and the chromosome
nucleotide position is given above the line. The red lines correspond to proteins which are coded on the minus strand; however all of the nucleotides referred to are shown as
coding strand for that particular gene. The code for the mutation sites is: red = splice acceptor mutation; blue = splice donor mutation; black = point mutation to stop codon;
green = frameshift. Additional non-synonymous single nucleotide variants that change a single residue have not been included in the diagram but are listed in the
Supplementary information.1). CACNA1B: G!A will convert a tryptophan residue into a stop codon, truncating the protein.2). CACNA1C: G!T is a splice acceptor mutation,
whereas C!T will convert a glutamine residue into a stop codon, truncating the protein.3). CACNA1H: CAAGCTCA!C is a 7 nucleotide deletion, causing a frameshift leading to
addition of 7 different amino acids followed by a stop codon—the original protein is 2347aa, this truncated protein is 1050aa. A deletion at position 1260920, TC!T, causes a
frameshift leading to a truncation (15 missense aa before the stop codon-truncated protein is 1406aa, the WT protein is 2347aa).4). CACNA1S: G!A will convert a tryptophan
residue into a stop codon, truncating the protein. T!C is a splice donor mutation.5). CACNA2D1: C!AC is an insertion, disrupting the amino acid code thereafter due to
frameshift. It will cause truncation of the protein.6). CACNA2D2: C!G will convert a tyrosine residue into a stop codon, truncating the protein. T!G is a splice donor
mutation. G!A will convert a tryptophan residue into a stop codon, truncating the protein.7). CACNA2D4: GC!C single nucleotide deletion causes a frameshift, changing the
following 21 amino acids and adding an additional 28 amino acids before a stop codon occurs. The original protein is 1137aa, this predicted mutated protein is 1165aa.8).
CACNB4: G!T will convert a glutamic acid residue into a stop codon, truncating the protein. NCBI reference numbers for the calcium channels sequences used: CACNA1B:
NM_000718; CACNA1C: NM_000719; CACNA1D: NM_000720; CACNA1E: NM_000721; CACNA1F: NM_001256789; CACNA1H: NM_001005407; CACNA1S: NM_000069;
CACNA2D1: NM_000722; CACNA2D2: NM_001005505; CACNA2D4: NM_172364; CACNB2: NM_201597; CACNB3: NM_000725; CACNB4: NM_000726.
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mutation has not yet been studied.
It has now been shown that there is an increased burden of
microdeletions and duplications (all included in the term copy
number variation) in schizophrenia but not in bipolar disorder
(International Schizophrenia Consortium, 2008; Green et al., 2015).
These copy number variations often involve multiple genes, so that
it is difﬁcult to identify with certainty the causative genes (for
review, see Doherty et al., 2012). For example, copy number
variation in CACNA1B has been observed in subjects with disruption
of the subtelomeric 9q34 region, but the rearrangements usuallyalso involve another gene, EHMT1, and the phenotype observed is
variable. In some cases, however, there was monogenic duplication
of the CACNA1B gene, with a phenotype including Autism Spectrum
Disorder (Yatsenko et al., 2012).
Other presynaptic markers have also been found to be
implicated in this spectrum of disorders, including the synaptic
scaffolding protein neurexin-1 encoded by NRXN1 (Doherty et al.,
2012). Neurexins are key molecules involved in synaptic function.
The a-neurexins have been found to organize active zones, by
promoting the functional coupling of voltage-gated Ca2+ channels
to presynaptic machinery (Missler et al., 2003). Neurexins are also
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together with other presynaptic proteins including calcium
channels (Fairless et al., 2008). Recently, rare exonic micro-
deletions and other mutations in NRXN1 have been linked with
schizophrenia (Walsh et al., 2008; Rees et al., 2014) and autism
(Szatmari et al., 2007; Iossifov et al., 2012; De Rubeis et al., 2014);
and early GWA studies provided some evidence for common
schizophrenia risk alleles existing in this gene (O’Dushlaine et al.,
2011). Although NRXN1 was not one of the 108 genes identiﬁed
from the recent schizophrenia GWA study (Schizophrenia Working
Group of the Psychiatric Genomics Consortium, 2014), it is of
interest that this study did implicate NLGN4, encoding a neuroligin,
which is a postsynaptic binding partner of neurexins.
For autism spectrum disorder, data relating to copy number
variations and deleterious single nucleotide variants have recently
been combined to show convergence on a few pathways, involving
chromatin modiﬁcation/transcription regulation, MAP kinase/
cellular signalling, and neuronal development/axon guidance.
CACNA1C, CACNA1B, and CACNA1F were included in this analysis in
the latter two gene networks (Pinto et al., 2014).
6. Pathophysiological Sequelae of CACNA1C Mutations and
Polymorphisms
In investigating whether SNPs, rare single nucleotide variants
and other genetic disruptions are associated with gain or loss of
function of the implicated channel subunits, it depends on the wayTable 1
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in this neuropsychiatric disease spectrum (Ripke et al., 2013). The
implicated SNPs include rs1006737 (Hamshere et al., 2013) and
rs2007044 (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014). Recent studies on the pathophysio-
logical consequences of these intronic risk alleles are divergent. It
has been found that there is a speciﬁc interaction of an enhancer
region, situated in the intron containing this SNP, with the
proximal CACNA1C gene promoter, which results in the risk variant
SNP being associated with reduced CACNA1C gene expression
(Roussos et al., 2014). Another recent study also reported that the
CACNA1C risk alleles rs1006737 and rs1024582 are associated with
decreased gene expression in post-mortem cerebellum, but not in
parietal cortex (Gershon et al., 2014). In contrast, in another study
of post-mortem human brain samples from dorsolateral prefrontal
cortex of control subjects, the homozygous rs1006737 risk allele
(AA) was associated with a small increase in CaV1.2 mRNA (Bigos
et al., 2010). Furthermore, in a study comparing induced neurons
derived from skin ﬁbroblasts, from subjects with either AA, AG, or
GG containing alleles, the presence of the homozygous rs1006737
risk allele AA also resulted in increased CACNA1C mRNA compared
to those with AG or GG. In parallel, these neurons exhibited
increased calcium current density for 10/11 risk allele lines
analysed (Yoshimizu et al., 2015). However, in one of the cell lines
analysed, homozygous for the risk genotype, there was lower
CACNA1C mRNA levels and lower calcium current density, and thus
the pattern is not completely penetrant (Yoshimizu et al., 2015).
Human functional studies, examining heterozygous and homo-
zygous individuals harbouring the risk allele for SNP rs1006737,
have identiﬁed alterations in brain function, using functional
magnetic resonance imaging (fMRI), associated with working
memory. However, these investigations are limited by examining
small numbers of subjects, and some contradictory results are
reported between the studies. Interestingly, in one study, healthy
carriers of the CACNA1C risk variant rs1006737 were found to have
a reduction of bilateral hippocampal activation during episodic
memory recall, and several other alterations (Erk et al., 2010). The
rs1006737 risk allele was also associated in a dose-dependent
manner with blunted reward responsiveness (Lancaster et al.,
2014). Another recent study compared the brain activity of healthy
rs1006736 risk allele carriers with matched controls (Paulus et al.,
2014). Here, a signiﬁcant decrease in activity in the dorsolateral
prefrontal cortex was observed, as well as a decrease the
connectivity with the medial temporal lobe during working
memory tasks, in those homozygous for the risk allele (Paulus
et al., 2014), which was the opposite result compared to a previous
study (Bigos et al., 2010). Although these two studies appear to be
confounding, the data are actually consistent with another study
that identiﬁed both increases and decreases in the capacity of
working memory in bipolar and schizophrenic rs1006737 carriers,
respectively (Zhang et al., 2012). It is also consistent with studies
that identiﬁed both increased and reduced expression of CACNA1C
in the presence of the rs1006737 risk allele (Bigos et al., 2010;
Roussos et al., 2014; Gershon et al., 2014) (Table 1).
A number of other behavioural and imaging studies have also
demonstrated alterations in individuals carrying the CACNA1C
rs1006737 risk allele, although again these are not always
consistent. An fMRI study of emotional processing in the amygdala
in bipolar, schizophrenic, and healthy control carriers of the
rs1006737 risk allele (AA/AG) found that the presence of the risk
allele affected amygdala activity during emotional processing
across all diagnostic groups (Tesli et al., 2013). Another study
showed a signiﬁcant association for alleles in intron 3 of CACNA1C
(both rs1006737 and the related SNP rs7959938) with increased
brainstem volume (Franke et al., 2010). However, an effect of the
rs1006737 risk allele on global grey matter volume which had beenidentiﬁed previously in healthy individuals (Kempton et al., 2009)
could not be conﬁrmed in this study (Franke et al., 2010).
7. Monogenic Disorders Resulting from Harmful Mutations in
Other Voltage-gated Calcium Channel Genes
7.1. CACNA1A
It is notable that this gene has not been implicated in the
spectrum of neuropsychiatric disorders discussed above. It
encodes the mainly presynaptic P/Q-type calcium channel
(CaV2.1), which is primarily essential for neurotransmitter release
at mature excitatory and inhibitory synapses and is also extremely
important in cerebellar function, being strongly expressed in
Purkinje neurons. Multiple dominant gain and loss of function
mutations in CACNA1A have been described in patients, resulting in
a spectrum of disorders: in particular, familial hemiplegic migraine
(FHM)-1, Episodic ataxia (EA)-2, spinocerebellar ataxia (SCA)-6,
and epilepsy. These diseases and their molecular basis have been
described in extensive recent reviews (Pietrobon, 2010; Pietrobon
and Moskowitz, 2013) and will not be covered in detail here. In
summary, mutations in CaV2.1 causing FHM1 are thought to result
in gain of function changes in CaV2.1 expression resulting in
increased excitatory synaptic function (Tottene et al., 2009) and
increased basal Ca2+ (Di Guilmi et al., 2014). In contrast, the mainly
truncating mutations that result in EA2 are due to loss of function,
with the possibility of dominant-negative action of the mutant
gene product (Jouvenceau et al., 2001; Page et al., 2004; Mezghrani
et al., 2008). The mechanism of SCA6, which results from an
increased CAG repeat of one C-terminal CaV2.1 splice variant, is
still unclear (Riess et al., 1997). The question remains as to whether
the pathology is due to altered CaV2.1 function or to the expanded
(21–30) CAG repeat region, which is nevertheless a relatively low
number of repeats that would not be deleterious in other CAG
expansion diseases (for discussion, see Pietrobon, 2010).
7.2. CACNA1B
Until recently, no mutations in CACNA1B, which encodes the
mainly presynaptic neuronal N-type calcium channel CaV2.2, had
been described in patients. Recently, one inherited gain of function
mutation has now been described, in the outer mouth of the
channel pore, which is found to be linked to a myoclonus-dystonia
syndrome (Groen et al., 2015), although this ﬁnding has been
disputed (Mencacci et al., 2015).
7.3. CACNA1C: Timothy Syndrome
This is an autosomal dominant genetic disorder affecting
multiple organs, but in particular displaying cardiac defects. It is
characterized primarily by prolonged QT syndrome, syndactyly,
and craniofacial abnormalities, although patients also exhibit
cognitive impairment, major developmental delays, and autism-
like behaviours (Splawski et al., 2004). The predominant genetic
causes are de novo missense mutations, particularly in mutually
exclusive exons 8 or 8a of CACNA1C, which encodes residues at the
base of domain I S6, associated with the activation gate. These
mutations are described as gain of function (Table 1), as they
involve loss of channel inactivation, which results in elevated Ca2+
entry (Splawski et al., 2004; Barrett and Tsien, 2008; Ramachan-
dran et al., 2013). In cardiomyocytes, the increased Ca2+ entry gives
rise to delayed repolarization of the action potential and
ventricular arrhythmias, which are the main cause of death.
The Timothy syndrome mutations are subdivided into TS1
mutations (G406R in exon 8a) and TS2 mutations (G406R or G402S
in exon 8). Tissue-speciﬁc differences in the expression of these
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exon 8 showing some variation in symptoms from those with a
mutation in exon 8a. It might be expected that calcium channel
blocking drugs would be of use in the treatment of Timothy
syndrome, but the gain of function mutations are in many cases
less sensitive to block, particularly by dihydropyridine antagonists,
because of the loss of inactivation (Splawski et al., 2004).
Recently, quite a number of other rare gain of function Timothy
syndrome mutations have been observed outside I S6. For example,
a mutation in exon 27 (I1166T), which is predicted to be at the base
of domain III S6, results in an increased window current (Boczek
et al., 2015). Also a patient with an A1473G mutation, predicted to
be in domain IV S6, had a complex phenotype including seizures
(Gillis et al., 2012), and G1911R, in the C-terminus, leads to a multi-
organ syndrome including seizures and developmental delay
(Hennessey et al., 2014).
Of relevance to the GWA studies described above, a patient with
a G402S mutation in exon 8, for which he is a mosaic, developed
bipolar disorder when aged 22 (Gershon et al., 2014). Relevant to
this, heterozygous knock-in mice, expressing a human TS2
mutation (G406R) at a low level, show behavioural changes
consistent with autistic-like behaviour (Bader et al., 2011).
Furthermore, neurons derived from induced pluripotent stem
cells from patients with the G406R mutation show multiple
changes in gene expression, probably secondary to altered
CaV1.2 function (Pasca et al., 2011) and also exhibit activity-
dependent dendrite retraction (Krey et al., 2013).
7.4. CACNA1D
The CaV1.3 channels encoded by CACNA1D are L-type calcium
channels which are important for pacemaker activity in the
sinoatrial node and brain, as well as in hearing, as identiﬁed by a
rare recessive human loss of function mutation, which gives rise to
sino-atrial node dysfunction and deafness (SANDD) syndrome
(Baig et al., 2011). Somatic gain of function mutations have been
identiﬁed in CACNA1D in aldosterone producing adenomas in the
adrenal zona glomerulosa (Azizan et al., 2013; Scholl et al., 2013).
These mutations are concentrated in the pore region, the activation
gate, and the voltage sensors and include mutations in exon 8a, in a
striking parallel to those in Timothy syndrome. Furthermore,
germline gain of function mutations were also found, identical to
two of the somatic mutations (G403D and I770M), in patients with
juvenile hypertension resulting from hyperaldosteronism (Scholl
et al., 2013). These patients also displayed a complex neurological
syndrome including cerebral palsy.
It is interesting that two of the mutations described above to be
associated with autism spectrum disorder (G407R and A749G)
(Iossifov et al., 2012; O’Roak et al., 2012; De Rubeis et al., 2014)
were located near to the residues mutated in patients with primary
aldosteronism and neurological deﬁcits. In the brain, L-type
calcium channels, including CaV1.3, play a role in the pacemaker
activity in brain dopaminergic neurons (Guzman et al., 2009; Liu
et al., 2014), and CaV1.3 is also involved in synaptic pruning during
development (Hirtz et al., 2012), two processes whose disruption
might be likely to be implicated in psychiatric disorders (for
review, see Striessnig et al., 2014). It is likely that the CACNA1D gain
of function mutations resulting in autism may have a milder effect
on channel function, whereas severe gain of function mutations
result in more extensive disability and hyperaldosteronism (Scholl
et al., 2013; Pinggera et al., 2015) (Table 1).
7.5. CACNA1H
Rare missense mutations in CACNA1H were found in 6 of
461 individuals with autism spectrum disorder. R212C and R902Ware in domain I and domain II voltage sensors, W962C is in domain
II pore, and A1874V is in the proximal C terminus. However, some
of the mutations were also present in unaffected family members,
indicating that the mutations are not fully penetrant. However, all
these mutations reduced CaV3.2 function in an expression system
(Splawski et al., 2006). It should also be noted that gain of function
mutations in CaV3.2 have been linked to childhood absence
epilepsy (Chen et al., 2003; Khosravani et al., 2004) and also to
hypertension associated with hyperaldosteronism (Scholl et al.,
2015).
7.6. CACNA2D1
The a2d-1 protein, encoded by CACNA2D1, is highly expressed
in skeletal, cardiac, and smooth muscle, as well as in the brain (Ellis
et al., 1988; Jay et al., 1991; Klugbauer et al., 1999). Mutations in
CACNA2D1 have been found to be associated with cardiac
dysfunction, including Brugada (Burashnikov et al., 2010) and
short QT (Templin et al., 2011; Bourdin et al., 2015) syndromes.
However, no central phenotypes have been identiﬁed in humans,
possibly because most neurons contain more than one subtype of
a2d subunit and these proteins may have a partially interchange-
able function. Nevertheless, in homozygous cacna2d1 knockout
mice, a mechanosensory and pain phenotype (Patel et al., 2013), as
well as abnormal cardiac function (Fuller-Bicer et al., 2009) have
been documented.
7.7. CACNA2D2
Two human family pedigrees with recessive mutations in
CACNA2D2, encoding a2d-2, causing infantile epileptic encepha-
lopathy have been found (Pippucci et al., 2013; Edvardson et al.,
2013). The carriers had no phenotype, in agreement with the lack
of phenotype in heterozygote mice lacking cacna2d2 expression,
despite the homozygous knockout mice having a major ataxic and
epileptic phenotype (Barclay et al., 2001; Brill et al., 2004).
7.8. CACNB4
b4, encoded by CACNB4, is widely expressed in the brain and is
one of the main b subunits associated with neuronal calcium
channels (for review, see Dolphin, 2003). Its involvement in
neurological disease was ﬁrst suggested by studies on the lethargic
mouse strain (Burgess et al., 1997). Furthermore, a truncating
mutation (loss of 38 C-terminal residues of b4) has been found in
patients with generalised epilepsy and ataxia (Escayg et al., 2000).
A particular b4 splice variant is also localised in the nucleus
(Hibino et al., 2003) and it may therefore have additional functions
on gene expression (Etemad et al., 2014).
8. Changes in Calcium Channel Gene Expression in Disease
A number of studies have been performed to examine changes
in gene expression of ion channels, including calcium channel
subunits, in post-mortem brains from patients with neuropsychi-
atric diseases (Iwamoto et al., 2004; Smolin et al., 2012). However,
there are many confounding factors that affect such studies,
including the fact that patients have been exposed to a variety of
drugs, making it difﬁcult to reach ﬁrm conclusions. In one study,
expression of CACNA1A mRNA measured by microarray assay was
down-regulated in post-mortem brains of 11 patients with bipolar
disorder, although this was not conﬁrmed by RT-PCR studies
(Iwamoto et al., 2004). In another study, changes in expression of
some calcium channel b subunit mRNAs were observed in some
brain regions, in 14 patients each with bipolar disorder,
schizophrenia, or major depression (Smolin et al., 2012), but
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drug treatment make ﬁrm conclusions difﬁcult. There are,
however, several other neuropsychiatric disorders in which gene
expression changes do occur, as described below.
8.1. Fragile X Syndrome
Fragile X syndrome is the most common inherited form of
intellectual disability. Fragile X syndrome has a prevalence of 1 in
2500–4000 males and 1 in 6000–8000 females. People with Fragile
X syndrome show mild to moderate cognitive dysfunction,
frequently associated with autistic spectrum disorders (Bhakar
et al., 2012). In addition, Fragile X syndrome patients often display
peripheral autonomic and sensory symptoms, including height-
ened tactile sensitivity and gastrointestinal motility changes
(Boyle and Kaufmann, 2010). Fragile X syndrome results from
the partial or complete loss of Fragile X mental retardation protein
(FMRP) expression and function. FMRP is present both in the
nucleus and the cytoplasm and is a component of cytoplasmic RNA
granules, where it serves both to trafﬁc-speciﬁc mRNAs to sites of
translation and to stall their translation (Bassell and Warren, 2008;
Darnell et al., 2011). Loss of FMRP in fmr1 knockout mice results in
dysregulation of mRNA translation (Bassell and Warren, 2008) and
an alteration of synapse number and shape (Antar et al., 2006).
Research has concentrated particularly on the dendritic/postsyn-
aptic role of FMRP (Ronesi and Huber, 2008; Krueger and Bear,
2011). Loss of FMRP results in excessive and unregulated dendritic
mRNA translation (Antar et al., 2004; Bassell and Warren, 2008).
However, there is now increasing evidence for an additional
presynaptic role of FMRP. Loss of presynaptic FMRP reduces
functional synapse formation (Hanson and Madison, 2007),
decreases the size of the presynaptic active zone and synaptic
vesicle number, and affects presynaptic protein levels (Klemmer
et al., 2011). Granules containing FMRP have been identiﬁed in
central presynaptic terminals and axons, being particularly
prevalent during synapse maturation (Christie et al., 2009). Recent
studies also describe a role for FMRP in local protein synthesis in
peripheral sensory axons (Price et al., 2006). Although fmr1
knockout mice exhibit normal acute nociceptive responses, they
show alterations in chronic responses, both peripherally and
centrally (Price et al., 2007). As described above, heightened tactile
sensitivity and self-injurious behaviour is observed in some Fragile
X syndrome patients and this could be related to dysregulation of
nocifensive behaviour (Price et al., 2007).
Several calcium channel mRNAs have been identiﬁed as FMRP
targets, suggesting they would be upregulated as a result of loss of
FMRP, including CACNB3 and CACNA1C (Darnell et al., 2001; Brown
et al., 2001), and more recently a larger array of calcium channel
genes including CACNA1A, CACNA1B, CACNA1E, CACNA1G, CACNA1I,
CACNB1, and CACNB3 (Darnell et al., 2011). In addition to its role as
an RNA binding protein, FMRP has also been shown to associate
with ion channels. FMRP has been shown to interact with, and
modify the activation of, both sodium-activated K+ channels
(Brown et al., 2010) and calcium-activated K+ channels (Deng et al.,
2013). It has also recently been shown that FMRP interacts with
voltage-gated calcium channels and modulates presynaptic
neurotransmitter release (Ferron et al., 2014). Furthermore, it is
relevant to mention here that rare alleles in a number of FMRP
targets have been associated with schizophrenia across multiple
studies (Fromer et al., 2014; Purcell et al., 2014).
8.2. Neuropathic Pain
While changes in calcium channel gene expression have not
been widely reported in neurological and psychiatric diseases, in
neuropathic pain this phenomenon is widely observed followingdamage to peripheral nerves, which have the capacity for
regeneration. Peripheral sensory nerve damage has as one of its
sequelae the change in transcription of many genes, which may be
either up- or down-regulated (Newton et al., 2001; Wang et al.,
2002; Xiao et al., 2002; Davis-Taber and Scott, 2006). These gene
expression changes have a major role in the development and
maintenance of chronic pain that long outlasts the injury. One of
the many molecular consequences of experimental peripheral
nerve injury is an increase in the level of a2d-1 mRNA in damaged
sensory dorsal root ganglion neurons, shown by in situ hybridiza-
tion (Newton et al., 2001), microarray analysis (Wang et al., 2002;
Xiao et al., 2002; Davis-Taber and Scott, 2006), PCR (Luo et al.,
2001), and quantitative PCR (Bauer et al., 2009). There is also an
alteration in expression of a2d-1 splice variants, with concomitant
pharmacological consequences (Lana et al., 2014). In contrast to
a2d-1, the mRNA for a2d-2 and a2d-3 has been shown to be down-
regulated in rat dorsal root ganglion neurons following nerve
injury (Bauer et al., 2009).
Sensory nerve damage may occur due to direct physical trauma,
or it may be a result of poorly regulated plasma glucose in diabetes,
herpes virus infection, certain chemotherapeutic drugs, and other
causes. The injury-induced increase in a2d-1 protein occurs in
dorsal root ganglion somata and in their axons and central
terminals in the spinal cord, as determined by Western blot (Luo
et al., 2001) and immunohistochemistry (Bauer et al., 2009). In
contrast, mRNA and protein for the main calcium channel a1
subunit involved in pain transmission (CaV2.2) is not up-regulated
following sensory nerve damage (Wang et al., 2002; Li et al., 2006),
although there is a change in splicing (Altier et al., 2007). This leads
to the possibility that up-regulated a2d-1 enhances
CaV2.2 trafﬁcking and presynaptic function, although it may also
have other functions, separate from its role as a calcium channel
subunit (Eroglu et al., 2009). There is also no observed up-
regulation of b subunits reported in microarray (Wang et al., 2002;
Xiao et al., 2002; Davis-Taber and Scott, 2006) or other studies
(Lana et al., 2014). In contrast, CACNA1D expression has been
shown to be down-regulated two-fold in small dorsal root
ganglions (Davis-Taber and Scott, 2006).
9. Involvement of Voltage-gated Calcium Channels in Early
Brain Development
Although beyond the scope of this review, the role of neuronal
calcium spikes and waves during brain development and in the
establishment of neuronal circuitry is the subject of extensive
research (Gu et al., 1994; Nishiyama et al., 2011; Rosenberg and
Spitzer, 2011; Lepski et al., 2013). Calcium spikes are found in
neurons at the earliest stages of development (Gu and Spitzer,
1993; Desarmenien et al., 1993; Hirtz et al., 2012). These spikes
involve activity that is both spontaneous and also dependent on
networks. In one study, L-type calcium channels were found to be
involved in thalamocortical axon outgrowth (Mire et al., 2012).
Furthermore, it has also been observed that calcium spike activity
mediates dopaminergic and GABAergic speciﬁcation within the
ventral suprachiasmatic nucleus of Xenopus laevis. This speciﬁca-
tion is seen to be activity-dependent and is prevented by inhibiting
calcium transients (Marek et al., 2010; Lewis et al., 2014). Thus, it is
not surprising that subtle alterations in calcium channel function
can alter neuronal connectivity, inﬂuencing cognitive functions
later in life. For example, as reviewed recently (Lewis, 2011),
GABAergic neurotransmission in the dorsolateral prefrontal cortex
of subjects with schizophrenia has been found to be reduced in a
number of studies. The GABAergic neurons in question are
chandelier neurons which synapse onto the axon initial segment
of pyramidal neurons. How these neurons become dysfunctional in
schizophrenia remains to be determined, but disruption of speciﬁc
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cortical interneuron, which can subsequently disrupt network
activity and cortical integration (Del Pino et al., 2013). Further-
more, it has been shown in Drosophila melanogaster that dendritic
pruning during development occurs in a sequence of events
involving calcium transients, mediated by both CaV1 and
CaV2 calcium channels, which activate a calcium-activated
protease (calpain) pathway (Kanamori et al., 2013). Notably,
members of these three gene families (CACNA1C, CACNA1D, CAPN5)
are implicated in schizophrenia from the recent GWAS and whole
exome sequencing investigations described in Sections 5 and 6.
10. Conclusions and Perspectives
The many genome-wide investigations carried out in the last few
years have emphasized the massive polygenicity in populations,
where thousands of coding and non-coding loci are polymorphic,
some of which represent risk alleles for a variety of disorders, and
many of which are pleiotropic, spanning a number of disorders
including those reviewed here (Lee et al., 2013). Schizophrenia and
other psychiatric conditions are found to have a high heritability
(Owen, 2014). A large number of studies now indicate that the
genetic component of psychiatric disease is a result of a
combination of multiple fairly common alleles, represented by
SNPs, each with a small effect, together with a few very rare alleles,
represented by deleterious mutations and copy number variations,
which might produce a relatively large increased risk in a very small
subset of patients with the disorder (Malhotra and Sebat, 2012).
Thus, the genetic risk of complex phenotypes, represented by the
neuropsychiatric disorders described here, is conferred by a large
number of both rare and common alleles distributed across the
genome. The sum of these genetic risks will interact with the many
environmental risk factors that have been identiﬁed to be
associated with these diseases, including cannabis consumption
in the case of schizophrenia (Di Forti et al., 2014).
The voltage-gated calcium channel genes discussed in this
review, which are implicated in the aetiology of a spectrum of
psychiatric syndromes from bipolar disorder through schizophre-
nia to autistic spectrum disorder, are one piece of a jigsaw puzzle in
which synaptic proteins are strongly represented. Common and
rare mutations in numerous receptors and scaffolding proteins
that mediate mainly postsynaptic functions have been associated
with these diseases in multiple studies (Doherty et al., 2012;
Iossifov et al., 2014). However, although the rare variant
associations identiﬁed from exome sequencing studies largely
involve loss of function mutations, it is much less clear whether
common alleles associated with particular or multiple neuropsy-
chiatric disorders, identiﬁed in the GWA studies described here,
result in an up- or down-regulation of expression of the gene in
question (Table 1). Whether the presence of particular SNPs alter
the relative expression of channel splice variants, which may have
substantially different properties, is another possibility that has
not been explored.
10.1. Relative Roles of Pre- and Post-synaptic Calcium Channel
Dysfunction
It should be noted that most of the calcium channel genes
implicated in these studies do not have a primarily presynaptic
function; for example, the L-type channel CaV1.2 (encoded by
CACNA1C), which is strongly implicated as a risk gene across the
spectrum of psychiatric disorders discussed here, is not involved in
presynaptic fast transmitter release. These channels mainly play a
postsynaptic modulatory role, being located on cell bodies, as well
as on dendritic spines and shafts (Hell et al., 1993; Di Biase et al.,
2011; Hall et al., 2013). Here, they modulate dendritic processing(see, for example, Moosmang et al., 2005) and have a long-range
role in coupling neuronal activity to gene transcription (Wheeler
et al., 2012; Ma et al., 2013). It is of interest that distinct roles for
CaV1.2 and CaV1.3 were also found in several forms of memory
(Moosmang et al., 2005; Busquet et al., 2008; McKinney et al.,
2009), and in anxiety and depression-like behaviours in mice (Dao
et al., 2010; Lee et al., 2012). It is also important to realise that some
of the calcium channel genes implicated in these disorders are
expressed at extremely low levels in the brain, particularly CaV1.1
(encoded by CACNA1S) and CaV1.4 (encoded by CACNA1F)
(Sinnegger-Brauns et al., 2009). It is of course possible that these
transcripts have a signiﬁcant but transient role during develop-
ment and this could also be a fruitful area for research.
Regarding the involvement of presynaptic calcium channels,
although many calcium channel subunits have been associated
with the neuropsychiatric spectrum of disorders discussed in this
review, there is very little evidence for involvement of CACNA1A,
encoding CaV2.1, which is the key presynaptic channel involved in
neurotransmitter release at mature central synapses. In contrast,
alterations in CACNA1B, encoding CaV2.2, have been identiﬁed from
a number of GWA and whole exome sequencing studies. CaV2.2 is
more important for synaptic transmission early in development, at
least in rodents (Iwasaki et al., 2000). If the same is true in humans,
this may point to a neurodevelopmental role for the changes in the
CaV2.2 gene, observed in the neuropsychiatric studies. In contrast,
there are numerous Mendelian disorders involving CaV2.1, as
described above, whereas only one family has been found possibly
to have a disease-associated germline point mutation in CaV2.2
(Groen et al., 2015), although this has been disputed (Mencacci
et al., 2015).
A well-established pathway for modulation of presynaptic
calcium channels occurs via presynaptic G protein coupled receptors,
with dopamine receptors being particularly relevant to psychotic
disorders. It has recently been found that common alleles in the gene
encoding the dopamine D2 receptor, DRD2, which is the primary
target of the D2 antagonist antipsychotic drugs, have been associated
with schizophrenia by GWAS (Schizophrenia Working Group of the
Psychiatric Genomics Consortium, 2014). One of the primary effects
of dopamine acting on this receptor (which is coupled to
heterotrimeric G proteins of the Gi/Go class) is presynaptic inhibition
by activation of G protein activated inwardly rectifying K+ channels
(Liu et al., 1999), and inhibition of CaV2 calcium channels
(particularly CaV2.2, but also CaV2.1 and CaV2.3) (Yan et al., 1997;
Meir et al., 2000; Leroy et al., 2005). Block of D2 receptors by
antipsychotic drugs would have among their effects the relief of
presynaptic inhibition mediated by endogenous dopamine via these
pathways. It is also worth mentioning here that the cannabinoid CB1
receptor is in the same Gi/o coupled receptor superfamily as the
dopamine D2 receptor, and its activation can also mediate
presynaptic inhibition (Brown et al., 2003).
The other calcium channel subunits implicated in the GWA and
whole exome sequencing studies described here (different b and
a2d subunits) are auxiliary and will affect both CaV1 and
CaV2 families of channels. Many of the considerations described
above point to the dysfunctional involvement of these channels
either neurodevelopmentally, or that the disruption mainly
involves postsynaptic dendritic integration. This is also consistent
with these disorders as neurodevelopmental, particularly in terms
of gene expression, as this can alter the balance of neurons
containing particular neurotransmitters, and the synaptic contacts
which they form.
As we have attempted to summarise in Table 1, we have not
been able to discern a clear consensus concerning gain or loss of
function of the calcium channel gene products associated with the
various disorders which form the basis of this review, but since
intracellular Ca2+ is so important for cellular signalling processes,
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indeed in all cells, it is highly likely that dysregulation of these
calcium channels in either direction will cause disruption of neural
developmental pathways. A major challenge for the future is to
translate the psychiatric genetic ﬁndings reviewed here into
altered developmental and physiological function, involvement in
pathology, and potential for personalised and stratiﬁed treatments
for patients.
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